Document Detail

Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
MedLine Citation:
PMID:  24635387     Owner:  NLM     Status:  Publisher    
WHAT IS KNOWN AND OBJECTIVE: There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO).
RESEARCH DESIGN AND METHODS: Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO.
RESULTS: There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not enalapril, improved Lp(a) levels compared with baseline. The combination enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the enalapril/lercanidipine combination compared with single monotherapies.
WHAT IS NEW AND CONCLUSION: The combination enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
G Derosa; A Bonaventura; D Romano; L Bianchi; E Fogari; A D'Angelo; P Maffioli
Related Documents :
12738577 - Measurement of cardiac functioning in older adults with heart failure after exercise.
8335187 - Carbon dioxide retention and oxygen desaturation during gastrointestinal endoscopy.
23320147 - Causes of resistant hypertension detected by a standardized algorithm.
2762007 - Experimental study of reflectance spectrophotometric analysis of the dog's dural sac--i...
3107517 - Arterial regeneration over polydioxanone prostheses in the rabbit.
9154957 - Effects of fosinopril on the blood pressure and lipid profile of patients undergoing he...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-17
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  -     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014 John Wiley & Sons Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The regulatory network of cluster-root function and development in phosphate-deficient white lupin (...
Next Document:  QCM-Based Measurement of Bond Rupture Forces in DNA Double Helices for Complementarity Sensing.